These data suggest that the underlying biology of CAS is highly comparable, at least in some aspects, between dogs and humans and that COL1A1, ACTA2, and FAP can be used as markers of CAS in canine mammary carcinomas. This evidence concerns the gene ACTA2 and breast carcinoma.